Tivic Health CEO Jennifer Ernst to Highlight Strategic Biopharmaceutical Transformation at Emerging Growth September Virtual Conference
Jennifer Ernst, Chief Executive Officer of Tivic Health, is set to deliver a comprehensive presentation at the upcoming Emerging Growth September Virtual Conference, where she will outline the company’s significant strategic transformation and its pioneering role in the biopharmaceutical sector. The presentation is expected to provide investors, industry experts, and stakeholders with a thorough understanding of Tivic’s unique approach to addressing critical diseases by integrating both biochemical and bioelectronic systems within the human body.
A Strategic Pivot Toward Biopharmaceutical Innovation
Under Ernst’s leadership, Tivic Health has embarked on a transformative journey that redefines its position in the healthcare and biotechnology landscape. Historically recognized for its bioelectronic therapies, Tivic is now strategically expanding into the biopharmaceutical space. This evolution underscores the company’s commitment to leveraging advanced science and technology to develop innovative solutions capable of addressing serious medical conditions. By combining traditional biochemical approaches with state-of-the-art bioelectronic techniques, Tivic aims to create therapies that are not only effective but also uniquely positioned to modulate the body’s natural response to disease.
During her presentation, Ernst will delve into the strategic rationale behind this pivot. She will highlight how Tivic’s integrated approach offers a differentiated path in a highly competitive biopharmaceutical market. By uniting bioelectronics with biochemical drug development, the company is targeting mechanisms of action that few other firms currently explore, positioning Tivic as a potential leader in the development of next-generation therapies.
Licensing Milestones: Statera Biopharma’s TLR5 Agonist Portfolio
A pivotal element of Tivic’s biopharmaceutical strategy is the licensing agreement secured in February 2025 with Statera Biopharma, granting Tivic access to a late-stage TLR5 agonist portfolio. This acquisition represents a major step forward in the company’s growth trajectory, providing access to a highly de-risked drug candidate with an established Phase III clinical indication, alongside multiple additional opportunities for therapeutic development.
At the center of this portfolio is Entolimod, Tivic’s lead commercial candidate. Originally developed as a military countermeasure to protect against lethal levels of ionizing radiation, Entolimod is now being repurposed for broader clinical applications, including the treatment of Acute Radiation Syndrome (ARS). Ernst will detail the significance of Entolimod within Tivic’s pipeline, emphasizing its potential to address an urgent and underserved medical need while advancing the company toward commercialization.
The CEO will also provide insights into the milestones achieved by Tivic since acquiring the TLR5 agonist portfolio, including regulatory progress, clinical development updates, and strategic initiatives designed to maximize the therapeutic potential of Entolimod. These developments reflect Tivic’s commitment to building a robust biopharmaceutical pipeline capable of delivering high-impact treatments to patients with serious medical conditions.
Expanding Opportunities: Addressing Neutropenia
Beyond Entolimod’s primary indication for ARS, Tivic is actively developing therapies for Neutropenia, a condition marked by abnormally low white blood cell counts. This deficiency compromises the body’s ability to fight infection and affects a wide range of patients, from those undergoing cancer treatments to individuals with genetic predispositions or age-related immune decline.
Ernst will discuss the clinical rationale for targeting Neutropenia and how Tivic’s bioelectronic-biochemical approach may offer unique advantages over existing therapies. She will also explore the market potential for treatments addressing Neutropenia, highlighting the substantial unmet need and the opportunity for Tivic to establish a meaningful presence in this therapeutic area. By leveraging Entolimod and other candidates from the TLR5 agonist portfolio, Tivic aims to develop safe, effective, and scalable solutions for patients who currently face limited treatment options.
Integration of Bioelectronics and Biopharmaceutical Innovation
A core theme of Ernst’s presentation will be the integration of bioelectronic technology with biopharmaceutical development. Tivic’s approach is rooted in the understanding that complex diseases often require multifaceted interventions. By combining drug therapies with bioelectronic modulation, the company is exploring ways to enhance efficacy, reduce side effects, and target disease mechanisms more precisely than conventional therapies alone.
Ernst will provide examples of how this integration works in practice, highlighting preclinical and early clinical data that demonstrate the potential of Tivic’s innovative approach. She will also discuss ongoing research initiatives designed to expand the application of bioelectronic-biochemical therapies across a variety of disease states, from immune modulation to tissue repair and beyond.
Commercialization Strategy and Future
An essential aspect of the presentation will be Ernst’s discussion of Tivic’s commercialization strategy for Entolimod and other pipeline candidates. This includes regulatory pathways, strategic partnerships, manufacturing capabilities, and market access plans. Ernst will emphasize how Tivic’s unique positioning—combining late-stage, de-risked drug candidates with proprietary bioelectronic technologies—creates a compelling opportunity for investors and partners alike.
Attendees can expect an in-depth overview of the company’s short-term and long-term goals, including upcoming clinical milestones, projected timelines for regulatory submissions, and strategies for broadening market reach. Ernst will also provide context on how Tivic’s transformation aligns with broader trends in precision medicine, bioelectronics, and biopharmaceutical innovation.
Interactive Q&A Session
To foster engagement with the investment community and industry stakeholders, Tivic encourages attendees to submit questions in advance. Ernst will address these inquiries during the presentation, offering insights into Tivic’s strategy, technology, and future growth prospects. This interactive component allows participants to gain a deeper understanding of the company’s vision and to engage directly with its leadership team.
Positioning Tivic as a Leader in Next-Generation Therapeutics
Overall, the presentation at the Emerging Growth September Virtual Conference represents a significant opportunity for Tivic Health to showcase its evolution from a bioelectronic-focused company into a fully integrated biopharmaceutical innovator. By combining biochemical drug development with bioelectronic systems, Tivic is uniquely positioned to address critical unmet medical needs and to develop therapies that could transform the standard of care across multiple disease areas.
Under Jennifer Ernst’s leadership, Tivic is not only advancing its late-stage pipeline but also setting a foundation for sustainable growth, innovation, and value creation for patients, partners, and investors. Ernst’s presentation promises to provide a comprehensive overview of these strategic initiatives, highlighting the milestones achieved, the opportunities ahead, and Tivic’s commitment to delivering meaningful impact in the healthcare industry.
As the healthcare and biopharmaceutical sectors continue to evolve rapidly, Tivic’s integrated approach positions the company at the forefront of innovation, blending science, technology, and patient-centric solutions. Investors, healthcare professionals, and industry observers attending the Emerging Growth conference will gain a valuable perspective on how Tivic is leveraging its unique capabilities to address pressing medical challenges and create long-term value in the biopharmaceutical landscape.
